Company intelligence / Profile preview

NeoCodex

Seville, Andalusia, Spain

Ownership: Private
Development stage: Other

Overview

NeoCodex was a Spanish biotechnology company specializing in pharmacogenomics and personalized medicine. Founded in 2000 and headquartered in Seville, the company focused on identifying genetic markers that influence drug response and disease susceptibility. NeoCodex developed a proprietary platform for high-throughput genetic analysis and managed one of Spain's most significant private DNA biobanks. Their product portfolio included genetic diagnostic tests for cardiovascular risk and obesity, such as Cardio inCode and Obesi inCode. In 2010, NeoCodex was acquired by Gendiag to integrate its genomic research capabilities into a broader diagnostic and personalized medicine strategy.

Therapeutic areas: EndocrinologyCardiovascularNeurology
Modalities: Genetic testingDiagnostic
Industry: Molecular Diagnostics

Partnerships

Ferrer

Beyond the preview

Go deeper on NeoCodex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeoCodex.

Explore the full profile